[PDF] Committee for Medicinal Products for Human Use (CHMP) issues positive opinion for license extension of trastuzumab emtansine (Kadcyla)

European Medicines Agency - EMA
European Medicines Agency
Publication date:
15 November 2019


The proposed license extension is for adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.